You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In using the act, the HHS applied priority-rated orders for SARS-CoV-2 diagnostic supply contracts with Becton Dickinson and Quidel through September.
Quidel sued Siemens Healthineers claiming false advertising associated with a competing assay that measures thyroid-stimulating immunoglobins to detect Graves' disease.
The governors of the six states are collaborating with the Rockefeller Foundation to expand access to point-of-care antigen testing for SARS-CoV-2.
Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.
CEO Doug Bryant noted, in particular, what he expects will be a hunger for rapid protein-based antigen tests for the coronavirus that the market currently can't fill.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
The firm saw $109 million in sales of its COVID-19-related products, including nearly $53 million in sales of its Lyra SARS-CoV-2 molecular diagnostic assay.
The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.
The announcement follows a similar one from Becton Dickinson saying that HHS would buy its tests and platforms for coronavirus testing.
The firm's revenues were stronger than expected, due primarily to demand for its COVID-19 molecular diagnostic and rapid immunoassay products.